A carregar...
Sublethal exposure to alpha radiation ((223)Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
Radium-223 dichloride (Xofigo(®); (223)Ra) is an alpha-emitting radiopharmaceutical FDA-approved for the treatment of bone metastases in patients with advanced castration-resistant prostate cancer. It is also being examined clinically in patients with breast and lung carcinoma and patients with mult...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5341329/ https://ncbi.nlm.nih.gov/pubmed/27893426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13520 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|